Safety and efficacy of GVD and anti-PD-1 (SHR-1210) regimen with or without low-dose decitabine priming for refractory bulky and aggressive primary mediastinal large B-cell lymphoma.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.7556
Abstract: 7556Background: Relapsed/refractory PMBCL (rrPMBCL) generally has limited treatment options and dismal prognosis. Recently, monotherapy of anti-PD-1 was reported to induce an effective and durable ... read more here.
Keywords: shr 1210; anti shr; efficacy gvd; safety efficacy ... See more keywords